Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122954 · ClinicalTrials.gov registry record · Phase 1
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00122954 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 39 participants.
The verdict
NCT00122954, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication. Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomery-Asberg depression rating scale (MADRS) or Beck Depression Inventory (BDI) better than placebo.
Interventions
- DRUG Placebo
- DRUG Fish oil concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122954
The ClinicalTrials.gov registry entry for NCT00122954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00122954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00122954 about?
NCT00122954 is a clinical study titled "Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis". This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication. Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomer...
What is the current status of trial NCT00122954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2005-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00122954?
The interventions under investigation include: Placebo (DRUG), Fish oil concentrate (DRUG).
Who is sponsoring clinical trial NCT00122954?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.